Call us @ +91-7889243106, +91-9888382488 email: info@trustcare.me

Selected:

Noxdril-Spray

530.00 450.50

Sale!

Noxdril-Spray

530.00 450.50

Noxdril- Solution/Spray regrow hairs, applied to the scalp is used to stimulate hair growth in adult men and women with a certain type of baldness.

Indications:

  • Alopecia
  • Alopecia Areata
  • chemotherapy-induced alopecia
  • Traction Alopecia

Description

Information about Noxdril-solution

Noxdril- Solution/Spray regrow hairs, applied to the scalp is used to stimulate hair growth in adult men and women with a certain type of baldness.
Each 60ml Pack contains:
Minoxidil 5%
Indications/Doses:
For the treatment of alopecia.
for alopecia androgenetica.
Topical dosage (2% minoxidil topical solution)
Adult men and women

Apply 1 ml twice daily topically, to area where hair growth is desired. Maximum dosage is 2 ml/day applied topically.

Topical dosage (5% minoxidil topical solution)
Adult men

Apply 1 ml twice daily topically, to area where hair growth is desired. Maximum dosage is 2 ml/day applied topically.

for alopecia areata†.
Topical dosage (5% minoxidil topical solution)
Adult men and women

1 ml twice daily topically led to terminal hair regrowth in 29 of 36 patients (81%) with extensive scalp hair loss.

for chemotherapy-induced alopecia†.
Topical dosage (2% minoxidil topical solution)
Adult women

1 ml twice daily applied topically throughout chemotherapy and up to 4 months post-chemotherapy decreased the duration of alopecia caused by treatment with fluorouracil, doxorubicin, cyclophosphamide. The period of baldness was shortened by a mean of 50.2 days.

for traction alopecia†.
Topical dosage (2% minoxidil topical solution)
Adult women

1 ml twice daily applied topically was found to be effective in two case reports. New hair growth was visible after 3 months of treatment, and convincing growth was evident at 6—9 months of continuous treatment.

for prevention of hair shedding following hair transplantation.
Topical dosage (2% minoxidil topical solution)
Adult men

1 ml twice daily applied topically reduced postoperative shedding and improved regrowth of hair in a study of 16 patients with androgenetic alopecia undergoing hair transplantation. Minoxidil was used for 4 weeks prior to surgery, stopped for 3 weeks, and then resumed again for 3 months.

PRECAUTIONS:
General Information

Minoxidil is contraindicated in patients with a history of minoxidil hypersensitivity.

Minoxidil has been reported to produce cardiac lesions in animals. Some lesions are characteristic of other drugs that can cause tachycardia and/or hypotension (e.g., isoproterenol, hydralazine). These effects are more likely to occur in patients with compromised renal function and in patients with connective tissue disease, uremic syndrome, CHF, or minoxidil-induced fluid retention.

Acute myocardial infarction, angina, cardiac disease, cardiac tamponade, cerebrovascular disease, coronary artery disease, hypotension, orthostatic hypotension, pericardial effusion, peripheral edema, requires a specialized care setting

Systemic minoxidil is a potent vasodilator with potential to produce hypotension and reflex tachycardia; serious complications may occur. Minoxidil is relatively contraindicated in patients with cardiac disease (including angina, coronary artery disease, recent or acute myocardial infarction), or cerebrovascular disease because a reflex increase in heart rate and decrease in blood pressure can exacerbate these conditions. Minoxidil is relatively contraindicated in patients with coronary insufficiency, including angina, to avoid the risk of reflex tachycardia and angina exacerbation. Minoxidil may cause pericardial effusion which occasionally may progress to cardiac tamponade. Reserve oral minoxidil for hypertension in patients who do not respond adequately to maximum therapeutic doses of a diuretic (loop diuretic suggested) concurrently with 2 other antihypertensive agents. In experimental animals, minoxidil has been shown to induce several types of myocardial lesions as well as other adverse cardiac effects. Minoxidil must be administered under close supervision, usually in combination with therapeutic doses of a beta-blocker to prevent reflex tachycardia and increased myocardial workload. Minoxidil is often given with a diuretic (preferably a diuretic which acts within the ascending limb of the loop of Henle) to prevent fluid accumulation and peripheral edema. When first administering minoxidil to patients with malignant hypertension and those already receiving guanethidine to avoid rapid or large orthostatic reductions in blood pressure, minoxidil use requires a specialized care setting, specifically hospitalization. Although minoxidil does not directly cause orthostatic hypotension, administration to patients receiving guanethidine can result in profound orthostatic effects. When possible, guanethidine should be discontinued well before minoxidil is initiated. Otherwise, minoxidil therapy should be started in the hospital; the patient should remain hospitalized until the risk of excessive orthostatic effects is minimized and the patient is able to avoid activities that induce orthostatic hypotension.

Pregnancy

Minoxidil is classified as pregnancy risk category C. Although no adequate human studies have examined the effects of this drug on the fetus, animal reproduction studies have shown adverse effects, including reduced ability to conceive and a reduced survival of offspring. Dysmorphic facial features and hypertrichosis were observed in an infant whose mother received a daily minoxidil dosage of 10 mg during pregnancy. Therefore, in making the decision to administer this drug during pregnancy, the potential risks to the fetus and possible difficulty in conceiving must be weighed against the potential benefits to the mother.

Breast-feeding

According to the manufacturer, minoxidil should not be administered to a nursing mother. The American Academy of Pediatrics (AAP) considers minoxidil to be generally compatible with breast-feeding ; however, other experts are less comfortable with the use of this potent antihypertensive agent in nursing mothers. In one case report of a woman taking minoxidil 5 mg PO twice daily, minoxidil was rapidly excreted into the breast milk. After two months, no adverse events were reported in the nursing infant. The effect of prolonged exposure during breast-feeding is unknown. Examples of other antihypertensives with more data in this population that have been classified as usually compatible with breast-feeding by the AAP and may be possible alternatives for some patients include enalapril, hydrochlorothiazide, methyldopa, and propranolol. It is not known whether topical minoxidil is distributed into breast milk. Consider the benefits of breast-feeding, the risk of potential infant drug exposure, and the risk of an untreated or inadequately treated condition. If a breast-feeding infant experiences an adverse effect related to a maternally administered drug, healthcare providers are encouraged to report the adverse effect to the FDA.

Children

The safety and efficacy of topical minoxidil products have not been established in children and adolescents.

Reviews

There are no reviews yet.

Be the first to review “Noxdril-Spray”

Your email address will not be published. Required fields are marked *

×
×

Cart